Systematic site rotationchanging locations with each weekly injection across multiple body areaseffectively prevents lipohypertrophy and maintains steady therapeutic levels of semaglutide
You dont need an appointment to start feeling better
Addiction, constipation, cognitive impairment, and risk for over-dose and respiratory depression create serious concerns
as a result, subcutaneous injections and intranasal delivery are the predominant methods used in research, though both routes present practical challenges for routine clinical use
Clinical trials demonstrated average weight reductions of 15-21% of body weight over 72 weeks in people with obesity (SURMOUNT-1), while more modest weight loss was observed in type 2 diabetes patients (SURPASS trials)
Comprehensive improvement in glycaemia, dyslipidaemia, hepatic steatosis, and cardiovascular markers